PCH
XENE icon

Polar Capital Holdings’s Xenon Pharmaceuticals XENE Stock Holding History

Polar Capital Holdings’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$276M Buy
4,570,556
+165,244
+4% +$9.17M 0.65% 41
2026
Q1 		$256M Buy
4,405,312
+1,939,618
+79% +$89.4M 0.91% 30
2025
Q4 		$111M Sell
2,465,694
-81,072
-3% -$3.4M 0.43% 63
2025
Q3 		$102M Sell
2,546,766
-156,490
-6% -$5.51M 0.49% 58
2025
Q2 		$84.6M Buy
2,703,256
+80,217
+3% +$2.62M 0.44% 61
2025
Q1 		$88M Sell
2,623,039
-74,618
-3% -$2.83M 0.54% 50
2024
Q4 		$106M Buy
2,697,657
+253,012
+10% +$10.5M 0.59% 47
2024
Q3 		$96.2M Sell
2,444,645
-91,413
-4% -$3.69M 0.46% 50
2024
Q2 		$98.9M Sell
2,536,058
-76,050
-3% -$3.04M 0.58% 45
2024
Q1 		$112M Sell
2,612,108
-454,520
-15% -$20.9M 0.59% 42
2023
Q4 		$141M Buy
3,066,628
+62,881
+2% +$2.22M 0.87% 21
2023
Q3 		$103M Sell
3,003,747
-18,324
-0.6% -$685K 0.76% 34
2023
Q2 		$116M Buy
3,022,071
+5,253
+0.2% +$209K 0.59% 33
2023
Q1 		$108M Sell
3,016,818
-29,056
-1% -$1.07M 0.7% 36
2022
Q4 		$120M Buy
3,045,874
+383,152
+14% +$14M 0.96% 22
2022
Q3 		$96.1M Buy
2,662,722
+122,663
+5% +$4.41M 0.61% 40
2022
Q2 		$77.3M Buy
2,540,059
+350,000
+16% +$10.6M 0.45% 54
2022
Q1 		$67M Buy
2,190,059
+502,015
+30% +$15M 0.3% 81
2021
Q4 		$52.7M Buy
+1,688,044
New +$50.4M 0.2% 100

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital Holdings's XENE Position: Q2 2026 in Review

Polar Capital Holdings increased its Xenon Pharmaceuticals (XENE) stake by 3.8% in Q2 2026, buying an estimated $9.17M and bringing the position to 4,570,556 shares worth $276M. The position accounts for 0.65% of the portfolio, ranked #41.

Polar Capital Holdings first reported a position in XENE in Q4 2021 and has held it in 19 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Polar Capital Holdings held 4,570,556 shares of Xenon Pharmaceuticals worth $276M as of Q2 2026.
  • Polar Capital Holdings bought 165,244 Xenon Pharmaceuticals shares in Q2 2026, an estimated $9.17M.
  • Xenon Pharmaceuticals made up 0.65% of Polar Capital Holdings's portfolio in Q2 2026, its #41 holding.
  • Polar Capital Holdings first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.